Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection

Gui-Qian Huang1,2,* , Gui-Qi Zhu1,3,* , Yan-Long Liu4,* , Li-Ren Wang1,3, Martin Braddock5, Ming-Hua Zheng1,6, Meng-Tao Zhou7

1Department of Infection and Liver Diseases, Liver Research Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
2Renji School of Wenzhou Medical University, Wenzhou 325000, China
3School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou 325000, China
4College of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China
5Global Medicines Development, AstraZeneca R&D, Alderley Park, United Kingdom
6Institute of Hepatology, Wenzhou Medical University, Wenzhou 325000, China
7Department of Hepatobiliary Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China

*Co-first author

Correspondence to: Ming-Hua Zheng, e-mail: zhengmh@wmu.edu.cn
Meng-Tao Zhou, e-mail: zmt0417@hotmail.com

Keywords: neutrophil-to-lymphocyte ratio, hepatocellular carcinoma, curative liver resection, overall survival.

ABSTRACT

Objectives: Neutrophil lymphocyte ratio (NLR) has been shown to predict prognosis of cancers in several studies. This study was designed to evaluate the impact of stratified NLR in patients who have received curative liver resection (CLR) for hepatocellular carcinoma (HCC).

Methods: A total of 1659 patients who underwent CLR for suspected HCC between 2007 and 2014 were reviewed. The preoperative NLR was categorized into quartiles based on the quantity of the study population and the distribution of NLR. Hazard ratios (HRs) and 95% confidence intervals (CIs) were significantly associated with overall survival (OS) and derived by Cox proportional hazard regression analyses. Univariate and multivariate Cox proportional hazard regression analyses were evaluated for association of all independent parameters with disease prognosis.

Results: Multivariable Cox proportional hazards models showed that the level of NLR (HR = 1.031, 95%CI: 1.002-1.060, P = 0.033), number of nodules (HR = 1.679, 95%CI: 1.285-2.194, P<0.001), portal vein thrombosis (HR = 4.329, 95%CI: 1.968-9.521, P<0.001), microvascular invasion (HR = 2.527, 95%CI: 1.726-3.700, P<0.001) and CTP score (HR = 1.675, 95%CI: 1.153-2.433, P = 0.007) were significant predictors of mortality. From the Kaplan-Meier analysis of overall survival (OS), each NLR quartile showed a progressively worse OS and apparent separation (log-rank P=0.008). The highest 5-year OS rate following CLR (60%) in HCC patients was observed in quartile 1. In contrast, the lowest 5-year OS rate (27%) was obtained in quartile 4.

Conclusions: Stratified NLR may predict significantly improved outcomes and strengthen the predictive power for patient responses to therapeutic intervention.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the third most common cause of mortality in the world and at least 300,000 of the 600,000 deaths worldwide occur in China alone [1]. Some population-based studies show that the incidence rate of HCC continues to approximate to the death rate, suggesting that the majority of patients with
HCC die with from this disease [2–3]. At present, curative liver resection (CLR) provides a radical therapy in patients with early stages of the disease, but is associated with a high-risk of recurrence and a poor long-term prognosis [4–6]. Therefore, it is necessary to monitor patients for progression of HCC to reduce the recurrence rate and to prolong the survival period in HCC patients after CLR.

Currently, several studies indicate that genetic, environmental, and biological factors contribute to risk factors for the development and progression of HCC [1–2, 7]. In addition, a number of clinicopathologic features have been identified as prognostic indicators for HCC patients, such as vascular invasion, tumor size, the level of serum a-fetoprotein (AFP) and bilirubin [8–11]. Of particular interest, recent studies show that systemic inflammatory responses lead to the promotion of angiogenesis, DNA damage, and tumor invasion through the upregulation of cytokines in many cancers [12–15]. The neutrophil—lymphocyte ratio (NLR), a marker of systemic inflammation, is a simple ratio of the absolute neutrophil and lymphocyte counts from the differential component of the blood leukocyte count, and it appears to perform a better prognosis of disease in patients with breast, gastric, lung, and rectal cancers [16–19]. Furthermore, an elevated level of pre-procedural NLR has shown a significant correlation with a poorer prognosis in patients undergoing liver transplantation for HCC [20], and a preoperative NLR ≥ 5 is an adverse predictor of disease-free and overall survival in HCC patients after curative resection [21]. Among patients with Hepato-pancreatico-biliary malignancy undergoing resection, elevated NLR is also a predictor of worse long-term outcome [22].

These studies have shown that the preoperative NLR has been a useful and informative prognostic marker in advanced diseases, including HCC. However, to date, there have been no reports regarding NLR in HCC patients undergoing CLR with stratification to predict overall survival. The main aim of this study was to construct the stratification with NLR to enhance the prognostic utility for patients who underwent CLR for suspected HCC.

RESULTS

Baseline characteristics of all patients in NLR quartiles

508 patients meeting the inclusion criteria from 1659 patients who received CLR for suspected HCC were selected into this study and were consisted of 432 males and 165 females with a mean age of 56.5 ± 10.9 years (range, 23 to 85) (Figure 1, Table 1). The majority of patients were male (85%), and Hepatitis B virus was the main etiology in this study (67.9%). According to the quartiles of NLR, all of the patients were divided into four groups, because this method ensured the most categories with adequate number of patients per category from the range of 0.54 to 38.5 (127 patients per group). The cut-off points of this stratification were: (Q1) 0.54–1.67, (Q2) 1.67–2.33, (Q3) 2.33–3.83 and (Q4) 3.83–38.5. The correlation of demographic, clinical, tumor and laboratory characteristics with NLR quartiles were shown in Table 1. There was no difference in the incidence of major complications and the demographic parameters among patients (all P > 0.05). Furthermore, patients with low and high NLR seemed to similar with regard to performance of laboratory characteristics except for total bilirubin, direct bilirubin, albumin, aspartate aminotransferase (AST), blood glucose, prothrombin time (PT), prothrombin time activity (PTA), INR and white blood cell. Because there were fewer numbers of patients in each quartile, some significant difference of baseline characteristics is reasonable.

DISCUSSION

In this study, the stratification of NLR level was first established to predict 36-month prognosis of patients who underwent CLR for HCC. Based on Kaplan-Meier analysis of OS, the elevated level of NLR was associated with the poor survival of liver cancer and high quartile of NLR was associated with poor prognosis. The association between tumors and inflammation was discovered over a century ago [23]. However, the mechanism by which the immune response may be triggered by a tumor is complex [24] and this has stimulated research for an underlying mechanism that associates tumor inflammation and disease prognosis.
Table 1: Characteristics of patients with hepatocellular carcinoma treated by surgical resection according to NLR quartiles

| Variables                      | All patients       | NLR quartiles                  |                   |                   |                   | P-value |
|--------------------------------|--------------------|--------------------------------|-------------------|-------------------|-------------------|---------|
|                                |                    | Quartile 1 n = 127             | Quartile 2 n = 127 | Quartile 3 n = 127 | Quartile 4 n = 127 |         |
|                                |                    | (0.54-1.67)                     | (1.67-2.33)         | (2.33-3.83)         | (3.83-38.5)       | <0.001  |
| NLR                            | 2.3 (1.7, 3.8)     | 1.3 (1.1, 1.5)                  | 2 (1.8, 2.2)       | 2.9 (2.5, 3.3)     | 7.5 (5.2, 12.4)   |         |

Demographic parameters

| Age (years)                  | 56.5 ± 10.9         | 55.4 ± 10.6                    | 56.6 ± 10.3        | 56.7 ± 10.9        | 57.2 ± 12.0       | 0.594   |
| Gender                       |                    |                                |                   |                   |                   |         |
| Male                         | 432 (85.0%)        | 105 (82.7%)                    | 108 (85.0%)       | 106 (83.5%)       | 113 (89.0%)       | 0.613   |
| Female                       | 76 (15.0%)         | 22 (17.3%)                     | 19 (15.0%)        | 21 (16.5%)        | 14 (11.0%)        |         |
| BMI (kg/m²)                  | 22.8 (20.8, 24.6)   | 22.9 (21.1, 24.5)              | 23.1 (21.1, 24.6) | 22.8 (20.9, 24.8) | 22 (20.3, 24.5)   | 0.550   |

Clinical parameters

| Ascites, n (%)                | 386 (90.2%)        | 105 (92.1%)                    | 102 (92.7%)       | 105 (93.8%)       | 74 (80.4%)        | 0.091   |
| Presence                     | 42 (9.8%)          | 9 (7.9%)                       | 8 (7.3%)          | 7 (6.2%)          | 18 (19.6%)        |         |
| Liver cirrhosis, n (%)       | 186 (42.8%)        | 48 (41.7%)                     | 43 (38.4%)        | 54 (47.8%)        | 41 (43.2%)        | 0.480   |

Etiology

| Hepatitis B, n (%)            | 341 (67.9%)        | 96 (76.1%)                     | 90 (70.9%)        | 81 (63.8%)        | 74 (60.7%)        | <0.001  |
| Alcohol, n (%)                | 40 (8.0%)          | 7 (5.6%)                       | 8 (6.3%)          | 13 (10.2%)        | 12 (9.8%)         |         |
| Hepatitis B + Hepatitis C, n (%)| 80 (15.9%)      | 19 (15.1%)                     | 21 (16.5%)        | 20 (15.7%)        | 20 (16.4%)        |         |
| Other, n (%)                  | 38 (7.6%)          | 4 (3.2%)                       | 7 (5.5%)          | 12 (9.4%)         | 15 (12.3%)        |         |
| Hepatitis C, n (%)            | 3 (0.6%)           | 0 (0.8%)                       | 1 (0.8%)          | 1 (0.9%)          | 1 (0.8%)          |         |

Laboratory parameters

| Total bilirubin (µmol/L)      | 10.0 (8.0, 15.0)   | 10.0 (8.0, 14.0)               | 9.0 (7.0, 14.0)   | 10.0 (7.0, 14.0)  | 13.0 (10.0, 22.0) | <0.001  |
| Direct bilirubin (µmol/L)     | 4.0 (2.8, 6.0)     | 3.0 (2.0, 5.0)                 | 3.0 (2.0, 5.0)    | 3.0 (2.8, 5.0)    | 5.0 (3.0, 8.5)    | <0.001  |
| Albumin (g/L)                 | 40.5 (37.3, 43.6)  | 39.9 (36.8, 43.2)              | 41.3 (38.2, 44.3) | 41.6 (38.5, 44.2) | 39.2 (35.1, 42.3) | <0.001  |
| ALT (IU/L)                    | 36.0 (25.0, 55.0)  | 38.0 (28.0, 50.0)              | 35.0 (25.0, 54.0) | 34.0 (23.0, 53.0) | 37.0 (24.8, 65.3) | 0.422   |
| AST (IU/L)                    | 37.0 (27.0, 54.0)  | 36.0 (29.0, 53.0)              | 34.0 (26.5, 49.5) | 33.0 (24.0, 51.0) | 41.0 (30.0, 85.0) | 0.004   |

(Continued)
| Variables                        | All patients       | Quartile 1 n = 127 (0.54-1.67) | Quartile 2 n = 127 (1.67-2.33) | Quartile 3 n = 127 (2.33-3.83) | Quartile 4 n = 127 (3.83-38.5) | P-value |
|---------------------------------|--------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|----------|
| Alkaline phosphatase (IU/L)     | 95.0 (75.0, 116.0) | 89.5 (74.3, 108.8)           | 98.0 (76.3, 114.0)           | 93.5 (73.3, 122.8)           | 98.5 (76.0, 135.0)           | 0.326    |
| γ-GT (IU/L)                     | 59.5 (34.3, 110.5) | 54.0 (34.3, 92.8)            | 58.0 (30.3, 119.3)           | 52.5 (33.0, 126.0)           | 71.5 (38.5, 124.8)           | 0.242    |
| Blood glucose (mmol/L)          | 5.9 (5.0, 7.3)     | 5.4 (4.8, 6.6)               | 6.0 (5.1, 7.8)               | 6.2 (5.2, 7.9)               | 6.0 (5.1, 7.9)               | <0.001   |
| Creatinine (μmol/L)             | 67.0 (56.0, 76.0)  | 67.0 (57.0, 77.0)            | 67.0 (57.0, 76.0)            | 66.0 (54.0, 74.0)            | 66.5 (57.0, 79.0)            | 0.626    |
| Serum sodium (mmol/L)           | 141.0 (139.0, 142.0) | 141.0 (139.0, 143.0)       | 141.0 (139.0, 143.0)         | 140.0 (139.0, 142.0)         | 140.5 (138.0, 142.3.0)       | 0.671    |
| PT (s)                          | 13.9 (13.3, 14.8)  | 14.0 (13.3, 14.9)            | 13.7 (13.2, 14.4)            | 13.8 (13.2, 14.4)            | 14.2 (13.6, 15.2)            | <0.001   |
| PTA (%)                         | 87.9 ± 13.8        | 85.6 ± 14                    | 91.1 ± 12.8                  | 91 ± 11.4                    | 83.9 ± 15.3                  | <0.001   |
| INR                             | 1.1 (1.0, 1.2)     | 1.1 (1.0, 1.1)               | 1.1 (1.0, 1.1)               | 1.1 (1.0, 1.1)               | 1.1 (1.0, 1.2)               | <0.001   |
| White blood cell (10^9/L)       | 5.3 (4.2, 6.7)     | 4.7 (3.8, 5.5)               | 5.4 (4.3, 6.3)               | 5.5 (4.5, 6.9)               | 5.9 (4.4, 8.8)               | <0.001   |
| AFP (ng/mL)                     | 30.4 (5.5, 452.2)  | 29.6 (5.4, 285.5)            | 51.1 (6.1, 943)              | 22.9 (5.0, 469.1)            | 28.6 (4.9, 413.6)            | 0.506    |
| Uric acid (μmol/L)              | 300.4 ± 91.4       | 312.4 ± 87.5                 | 300.5 ± 86.1                 | 294.7 ± 81                   | 293.9 ± 108.5                | 0.342    |
| Platelet (10^9/L)               | 140.3 ± 66.0       | 131.0 ± 56.1                 | 146.1 ± 62.4                 | 147.5 ± 67.0                 | 136.9 ± 76.1                 | 0.128    |

**Tumor Characteristics**

| Number of nodules | 0.007 |
|-------------------|-------|
| 1                 | 424 (87.2%) | 108 (87.8%) | 109 (87.2%) | 106 (84.8%) | 101 (89.4%) |
| 2                 | 41 (8.4%) | 10 (8.1%) | 11 (8.8%) | 13 (10.4%) | 7 (6.2%) |
| 3                 | 9 (1.9%) | 2 (1.6%) | 2 (1.6%) | 2 (1.6%) | 3 (2.7%) |
| ≥4                | 12 (2.5%) | 3 (2.4%) | 3(2.4%) | 4 (3.2%) | 2 (1.8%) |
| Greatest tumor diameter (mm) | 49.1 ± 33.0 | 37.1 ± 22.5 | 49.6 ± 29.6 | 52.1 ± 38.5 | 58.4 ± 36.1 | <0.001 |
| Portal vein thrombosis, n (%)  | 15 (3.5%) | 1 (0.9%) | 4 (3.6%) | 5 (4.5%) | 5 (5.4%) | 0.042 |
| Microvascular invasion, n (%)  | 133 (26.4%) | 38 (30.2%) | 27 (21.4%) | 28 (22.2%) | 40 (31.7%) | <0.001 |
| CLIP score         |       |       |       |       |       | <0.001 |

(Continued)
### Table 2: Univariate and multivariate Cox Proportional Hazards Regression Analyses of factors associated with Mortality

| Variables | All patients | NLR quartiles |
|-----------|-------------|---------------|
|           | Quartile 1 n = 127 (0.54-1.67) | Quartile 2 n = 127 (1.67-2.33) | Quartile 3 n = 127 (2.33-3.83) | Quartile 4 n = 127 (3.83-38.5) | P-value |
|           | 0, n (%) | 182 (44.5%) | 62 (59.5%) | 40 (38.8%) | 53 (48.1%) | 27 (31.7%) |
|           | 1, n (%) | 87 (21.3%) | 25 (22.5%) | 25 (24.3%) | 20 (18.2%) | 17 (20.0%) |
|           | 2, n (%) | 73 (17.8%) | 16 (14.4%) | 19 (18.4%) | 20 (18.2%) | 18 (21.2%) |
|           | 3, n (%) | 51 (12.5%) | 4 (3.6%) | 15 (14.6%) | 17 (15.5%) | 15 (17.6%) |
|           | 4, n (%) | 14 (3.4%) | 4 (3.6%) | 4 (3.9%) | 0 | 6 (7.1%) |
|           | 5, n (%) | 2 (0.5%) | 0 | 0 | 0 | 2 (2.4%) |
| CTP score | | | | | 0.031 |
| A, n (%) | 352 (83.0%) | 97 (85.1%) | 93 (85.3%) | 101 (91.0%) | 61 (67.8%) |
| B, n (%) | 64 (15.1%) | 14 (12.3%) | 15 (13.8%) | 9 (8.1%) | 26 (28.9%) |
| C, n (%) | 8 (1.9%) | 3 (2.6%) | 1 (0.9%) | 1 (0.9%) | 3 (3.3%) |

**Follow-up data**

| Death within 36 months of resection | Alive | Deceased | <0.001 |
|------------------------------------|-------|----------|--------|
| 0, n (%) | 145 (54.9%) | 34 (56.7%) | 34 (61.8%) | 40 (60.6%) | 37 (44.6%) |
| 1, n (%) | 119 (45.1%) | 26 (43.3%) | 21 (38.2%) | 26 (39.4%) | 46 (55.4%) |

**NOTE.** NLR, neutrophil-lymphocyte ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, γ-glutamyl transferase; PT, prothrombin time; PTA, prothrombin time activity; AFP, alpha-fetoprotein; INR, international normalized ratio; CLIP, Cancer of The Liver Italian Program; CTP, Child-Turcotte-Pugh.

(Continued)
NLR was frequently used as an inflammatory marker, and its prognostic role in liver cancer has recently been described [20,26–28]. The recent meta-analyses have confirmed the prognostic value of the NLR in HCC [29]. In addition, surgery in cancer patients has been shown to influence lymphocyte function, including reducing lymphocyte adenosine triphosphate production following hysterectomy, colostomy, and also after blood transfusion [30]. This was also been observed in HCC patients after CLR, some studies indicate that pre-operative NLR was an adverse predictor of disease-free and overall survival in these patients [21,31]. As the level of NLR is the widely accepted serum biomarker to diagnose cancer and predict the recurrence of cancer, we first stratified NLR to predict prognosis in patients who underwent CLR for HCC and to ask whether this could be used to predict a better performance. We found that the presence of elevated pre-operative NLR was associated with poor survival, which is consistent with the study of Walsh et al. who reported that NLR has been shown to be a biomarker of inflammation and of prognostic significance in colorectal carcinoma [24]. Furthermore, Zhao et al. demonstrated that an elevated level of NLR was associated with poor survival in patients with lung cancer [32].

| Variables                      | Univariate analysis | Multivariate analysis |
|-------------------------------|---------------------|-----------------------|
|                               | B       | HR   | 95%CI   | P-value | B       | HR   | 95%CI   | P-value |
| AST (IU/L)                    | 0.001   | 1.001| 1.000-1.002 | 0.005   |         |       |         |         |
| Alkaline phosphatase (IU/L)   | 0.002   | 1.002| 1.001-1.003 | 0.006   |         |       |         |         |
| γ-GT (IU/L)                   | 0.001   | 1.001| 1.000-1.002 | 0.047   |         |       |         |         |
| Blood glucose (mmol/L)        | 0.046   | 1.047| 1.004-1.092 | 0.032   |         |       |         |         |
| Creatinine (μmol/L)           | -0.004  | 0.996| 0.987-1.005 | 0.408   |         |       |         |         |
| Uric acid (μmol/L)            | 0.000   | 1.000| 0.998-1.002 | 0.978   |         |       |         |         |
| Serum sodium (mmol/L)         | 0.003   | 1.003| 0.998-1.008 | 0.276   |         |       |         |         |
| PT (s)                        | 0.152   | 1.164| 1.039-1.305 | 0.009   |         |       |         |         |
| PTA (%)                       | -0.015  | 0.985| 0.973-0.997 | 0.013   |         |       |         |         |
| INR                           | 0.008   | 1.008| 0.988-1.028 | 0.433   |         |       |         |         |
| White blood cell (10^9/L)     | 0.025   | 1.025| 1.009-1.041 | 0.002   |         |       |         |         |
| Platelet (10^9/L)             | 0.003   | 1.003| 1.000-1.005 | 0.038   |         |       |         |         |
| AFP (ng/mL)                   | 0.000   | 1.000| 1.000-1.000 | 0.007   |         |       |         |         |

Tumor Characteristics

|                                | Univariate analysis | Multivariate analysis |
|--------------------------------|---------------------|-----------------------|
|                                | B       | HR   | 95%CI   | P-value | B       | HR   | 95%CI   | P-value |
| Number of nodules              | 0.423   | 1.526| 1.225-1.901 | <0.001  | 0.518   | 1.679| 1.285-2.194 | <0.001  |
| Greatest tumor diameter (mm)   | 0.010   | 1.010| 1.005-1.014 | <0.001  |         |       |         |         |
| Portal vein thrombosis         | 1.778   | 5.919| 2.835-12.358 | <0.001  | 1.465   | 4.329| 1.968-9.521 | <0.001  |
| Microvascular invasion         | 0.897   | 2.453| 1.770-3.399 | <0.001  | 0.927   | 2.527| 1.726-3.700 | <0.001  |
| CLIP score                     | 0.445   | 1.560| 1.342-1.813 | <0.001  |         |       |         |         |
| CTP score                      | 0.691   | 1.996| 1.418-2.810 | <0.001  | 0.516   | 1.675| 1.153-2.433 | 0.007   |

NOTE. B, coefficient; HR, hazard ratio; CI, confidence interval; NLR, neutrophil-lymphocyte ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, γ-glutamyl transferase; PT, prothrombin time; PTA, prothrombin time activity; AFP, alpha-fetoprotein; INR, international normalized ratio; CLIP, Cancer of The Liver Italian Program; CTP, Child-Turcotte-Pugh.
produce myeloid growth factors leading to an increased production of neutrophils. For instance, granulocyte colony-stimulating factor, causes neutrophilia by acting specifically on bone marrow granulocytic cells [23,33–35]. An alternative explanation may be that a raised level of neutrophils may aid in the development of the neoplasm through providing an adequate environment for growth and proliferation [21]. In support of this, Kusumanto et al. found that the total circulating level of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor, is contained in granulocytes, especially in the neutrophils, which is thought to be involved in tumor development [36].

Recently, a number of studies in oncology have explored whether a better effect on disease prognosis can be achieved by stratification of an independent predictor, such as categorizing AFP into quintiles, creating the opportunity to observe differences in outcomes among HBV-HCC patients following surgical resection [37]. In this study, in view of the fact that the level of NLR is a widely accepted HCC risk factor, we categorized NLR into quartiles to investigate whether any enhanced predictive affect was detected. Consequently, we gained greater confidence in being able to predict clinical outcome, which was illustrated by a favorable outcome (the lowest quartile of NLR, with a 5-year survival of 60%) and a poor outcome (the highest quartile of NLR, with a 5-year survival of 27%). These new categories have shown distinct and significant survival outcomes in HCC patients, and so this may be helpful in guiding the clinician to predict the prognosis of disease and then to select the most appropriate treatment or palliative care. Hence, our study suggests that the stratification of NLR could independently contribute to the disease prognosis following CLR for suspected HCC.

The current study has several limitations. Our study requires further studies to further validate the performance of the stratification of NLR. Moreover, the findings may not be applicable to HCC patients who receive other therapies or surgeries [38], and data from further large-scale clinical researches are needed to evaluate the effect of categorizing NLR on patients who underwent CLR for suspected HCC. Finally, more predictive markers, such as the newly peritumoral Cbl and Na+/K+-ATPase α1 subunit [39–40], should be integrated into the prognostic system in the future.

In conclusion, we show for the first time a categorization of patients with pre-operative NLR into quartiles and that we may be able to predict significantly improved outcomes among HCC patients following CLR. We suggest that clinicians should consider the level of NLR to help select the most appropriate therapy plan for their patients with HCC.

**Figure 1: Study flow diagram.** HCC, hepatocellular carcinoma; PEI, percutaneous ethanol injection; RF, radiofrequency; TACE, transarterial chemoembolization.

1659 patients underwent hepatic resections with suspected HCC referred to the First Affiliated Hospital of Wenzhou Medical University from 1/2007 to 12/2014.

- 998 patients were excluded
  1) Non-HCC diseases according to postoperative pathological diagnosis (n = 215)
  2) Distant tumor metastasis (n = 176)
  3) Not the first primary cancer (n = 267)
  4) Multiple primary cancer (n = 107)
  5) Underwent hepatic resections before (n = 90)
  6) Underwent PEI, RF, TACE, liver transplantation before (n = 143)

661 patients were included

- Patients lost to follow-up were excluded (n = 153)

Total 508 patients were included
MATERIALS AND METHODS

Study design

In this study, all patients were sampled consecutively from CLR records for suspected HCC between January 2007 and January 2014 at the First Affiliated Hospital of Wenzhou Medical University. All cases of suspected HCC were confirmed by pathological analysis.

NLR was calculated by dividing the absolute level of neutrophils by the absolute level of lymphocytes on the basis of preoperative blood values. Furthermore, based on the quantity of the study population and the distribution of NLR with greatest differences in patient outcomes following surgery, NLR was further categorized into quartiles to investigate whether any enhanced predictive affect was detected while maintaining sufficient statistical power in each category. The study was performed according to Standards for the Reporting of Diagnostic Accuracy Studies, and it was approved by the Committee on the Ethics at the First Affiliated Hospital of Wenzhou Medical University while the written informed consents were obtained from all patients before the initiation of the study.

Exclusion criteria

For selection of patients into our analyses, the following exclusion criteria were used as follows: (1) non-
HCC disease on the basis of post-operative pathological diagnosis; (2) distant tumor metastasis; (3) not the first primary cancer; (4) multiple primary tumor; (5) previous history of hepatic resection; (6) previous history of radio-frequency treatment, or trans-catheter arterial chemoembolization, liver transplantation or percutaneous ethanol injection; (7) lost to follow-up. In total, 508 cases of HCC were identified and confirmed by post-operative pathology results.

Data collection and follow-up

Various items were abstracted from the patients’ medical records, including patient demographics, etiology of HCC, laboratory and clinical tests within the week prior to CLR. Clinical and demographic information included age, gender, BMI, laboratory tests, calculated The Cancer of the Liver Italian Program (CLIP) and Child-Turcotte-Pugh (CTP) score at initial presentation. The presence of microvascular invasion (MVI) was defined by evidence of tumor emboli in either the central hepatic vein, the portal, or the large capsular vessels on imaging studies or during surgical resection as we had previously described [41–42]. Clinical parameters such as ascites and liver cirrhosis (LC) were found by physical examination and confirmed by CT, abdominal ultrasonography or magnetic resonance imaging (MRI). Tumor characteristics included the number of tumor nodules on the basis of the CT or MRI scan, tumor size and portal vein thrombosis. Tumor size was defined as the maximal diameter of the tumor in imaging studies and portal vein thrombosis were observed during the surgery.

By March 2014 all postoperative patients were followed up once every 3 months. Death data of all-cause mortality were collected by the medical records, the social security death index as well as families, which guarantee the information of all decedents was obtained completely.

Statistical analysis

All categorical values were presented as number and proportions and compared with the Pearson’s chi-square test or Fisher’s exact test as appropriate. Continuous variables were judged for distribution type by using Kolmogorov-Smirnov test and reported as mean ± standard deviation (normal distribution) or median and interquartile range (abnormal distribution). And the differences of continuous variables between groups were evaluated by the one-way analysis of variance (ANOVA) or nonparametric Kruskal-Wallis test.

Hazard ratios (HRs) and 95% confidence intervals (CIs) were significantly associated with overall survival (OS) and derived by Cox proportional hazard regression analyses. The factors identified at univariate Cox proportional hazard regression analyses were further evaluated for association of all parameters with post-operative prognostic feature, and some of these with significant differences (p < 0.05) entered into a multivariate analysis to test whether to perform the significant effects while adjusting for multiple factors simultaneously. Then, the OS rates stratified by values of NLR were calculated using the Kaplan—Meier method and compared by the log-rank test.

For all analyses, a two-tailed p value of < 0.05 was considered to be of statistical significance. All statistical analyses were performed with SPSS version 18.0 (SPSS, Chicago, IL, USA) and MedCalc version 12.7 (MedCalc Software, Ostend, Belgium).

Abbreviation

AFP = alpha-fetoprotein, AKP = alkaline phosphatase, AST = aspartate aminotransferase, CI = confidence interval, CLR = curative liver resection, CT = computerized tomography, HCC = hepatocellular carcinoma, HR = hazard ratio, MRI = magnetic resonance imaging, LC = liver cirrhosis, MVI = microvascular invasion, NLR = neutrophil-to-lymphocyte ratio, OS = overall survival, γ-GT = γ-glutamyl transferase.

ACKNOWLEDGMENTS

Authors’ contributions: Gui-Qian Huang: data collection and analysis, interpreted data, drafted the manuscript. Gui-Qi Zhu: data collection, prepared figures and drafted the manuscript. Yan-Long Liu: data collection and prepared figures. Li-Ren Wang: prepared figures and data collection. Meng-Tao Zhou: data collection, statistical analysis and obtained funding. Martin Braddock: helped to draft the manuscript. Ming-Hua Zheng: designed the study, participated in its design, obtained funding and helped to draft the manuscript.

CONFLICTS OF INTEREST

The authors report no declarations of interest.

FUNDING INFORMATION

This work was supported by grants from National Natural Science Foundation of China (81500665, 81370563), Zhejiang Provincial Natural Science Foundation of China (LR14H030001), Ministry of Health of China—the Major Medicine Science and Technology Project in Zhejiang province (WKJ2012-2-033), Science and Technology Innovation Program of Zhejiang Province (2015R413068), and Project of New Century 551 Talent Nurturing in Wenzhou.
REFERENCES

1. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin S, Hamid SS, et al. Hepatocellular carcinoma (HCC): a global perspective. Journal of clinical gastroenterology. 2010;44:239-245.

2. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: a cancer journal for clinicians. 2012;62:394-399.

3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61:69-90.

4. Du ZG, Wei YG, Chen KF, Li B. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution’s experience with 398 consecutive patients. Hepatobiliary & pancreatic diseases international. 2014;13:153-161.

5. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary & pancreatic diseases international. 2008;7:237-257.

6. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Annals of surgery. 2002;235:373-382.

7. Kim do Y, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver cancer. 2012;1:2-14.

8. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524.

9. Wei K, Wang M, Zhang W, Mu H, Song TQ. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Medical oncology. 2014;31:969.

10. Tan CK, Law NM, Ng HS, Machin D. Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation. Journal of clinical oncology. 2003;21:2294-2298.

11. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48:103-109.

12. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. Journal of hepatology. 2013;58:58-64.

13. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.

14. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.

15. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer research. 2000;60:184-190.

16. Kim IY, You SH, Kim YW. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC surgery. 2014;14:94.

17. Kobayashi N, Usui S, Kikuchi S, Goto Y, Sakai M, Onizuka M, Sato Y. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung cancer. 2012;75:223-227.

18. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD. Usefulness of the neutrophil-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Annals of surgical oncology. 2012;19:217-224.

19. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, Kim YJ. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. Journal of surgical oncology. 2011;104:504-510.

20. Halazun KJ, Hardy MA, Rana AA, Woodard DCT, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, Brown RS, Jr., Emond JC. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Annals of surgery. 2009;250:141-151.

21. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World journal of surgery. 2008;32:1757-1762.

22. Spolverato G, Maqood H, Kim Y, Margonis G, Luo T, Ejaz A, Pawlik TM. Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies. Journal of surgical oncology. 2015;111:868-874.

23. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RJ. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. American journal of surgery. 2010;200:197-203.

24. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. Journal of surgical oncology. 2005;91:181-184.

25. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-444.

26. Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma. World journal of surgery. 2015;39:1501-1509.
27. Gao F, Li X, Geng M, Ye X, Liu H, Liu Y, Wan G, Wang X. Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine. 2015;94:e639.

28. Xu X, Chen W, Zhang L, Miao R, Zhou Y, Yan W, Dong Y, Liu C. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Chinese medical journal. 2014;127:4204-4209.

29. Xiao WK, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of neutrophil to lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC cancer. 2014;14:117.

30. Mukherjee M, Sahasrabuddhe MB. Effect of operation on peripheral lymphocyte counts and production of adenosine triphosphate (ATP) in cancer patients. Journal of surgical oncology. 1982;20:1-8.

31. Liao W, Zhang J, Zhu Q, Qin L, Yao W, Lei B, Shi W, Yuan S, Tahir SA, Jin J, He S. Prooperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection. Translational oncology. 2014;7:248-255.

32. Zhao QT, Yang Y, Xu S, Zhang XP, Wang HE, Zhang H, Wang ZK, Yuan Z, Duan GC. Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients. OncoTargets and therapy. 2015;8:2731-2738.

33. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood. 1996;88:335-340.

34. Ulich TR, del Castillo J, Watson LR, Yin SM, Garnick MB. In vivo hematologic effects of recombinant human macrophage colony-stimulating factor. Blood. 1990;75:846-850.

35. Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L, Dexter TM. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proceedings of the National Academy of Sciences of the United States of America. 1989;86:9499-9503.

36. Kusumanto YH, Dam WA, Hosphers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283-287.

37. Blank S, Wang Q, Fiel MI, Luan W, Kim KW, Kadri H, Mandeli J, Hiotis SP. Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal. Annals of surgical oncology. 2014;21:986-994.

38. Zhu GQ, Shi KQ, Yu HJ, He SY, Braddock M, Zhou MT, Chen YP, Zheng MH. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget. 2015;6:18151-18161. doi:10.18632/oncotarget.4098.

39. Zhang JB, Zhang B, Guo L, Lin ZH, Li XQ, Guo K, Sun HC, Ye QH. Peritumoral Cbl is a strong independent prognostic marker after curative resection of hepatocellular carcinoma. Oncotarget. 2015;6:40223-40234. doi:10.18632/oncotarget.5540.

40. Zhuang L, Xu L, Wang P, Jiang Y, Yong P, Zhang C, Zhang H, Meng Z, Yang P. Na+/K+-ATPase alphal subunit, a novel therapeutic target for hepatocellular carcinoma. Oncotarget. 2015;6:28183-28193. doi:10.18632/oncotarget.4726.

41. Vauthey JN, Lauwers GY, Ensaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, Cleary KR, Nagorney DM. Simplified staging for hepatocellular carcinoma. Journal of clinical oncology. 2002;20:1527-1536.

42. Huang S, Huang GQ, Zhu GQ, Liu WY, You J, Shi KQ, Wang XB, Che HY, Chen GL, Fang JF, Zhou Y, Zhou MT, Chen YP, et al. Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection. PLoS One. 2015;10:e0129000.